Applied DNA Sciences has undergone a significant corporate transformation, shifting from its traditional biotechnology focus to become a yield-focused BNB digital asset treasury company. The company announced it has been named a B2i Digital Featured Company, providing access to B2i Digital's investor network of over 1.4 million market participants through platforms including LinkedIn, X, and Facebook.
The strategic rebrand reflects Applied DNA's expansion beyond nucleic acid manufacturing to integrate digital asset management as a core business component. This pivot represents a fundamental change in corporate strategy, with the company now pursuing yield generation and token accumulation within the Binance ecosystem while maintaining its proprietary nucleic acid production technology as a supporting platform. The transformation is underscored by the company's ticker symbol change from "APDN" to "BNBX" effective October 7, 2025.
David Shapiro, CEO of B2i Digital, emphasized the significance of this corporate evolution, stating that Applied DNA's shift toward a BNB-centric digital asset treasury demonstrates innovation in corporate finance and shareholder alignment. The partnership with B2i Digital will enable Applied DNA to communicate its strategic transformation to retail and institutional investors across multiple digital channels, including Instagram, YouTube, and Stocktwits.
Applied DNA CEO Clay Shorrock explained that the collaboration with B2i Digital will help investors understand how the company's approach to digital asset management supports both growth objectives and balance-sheet strength. The company has secured approximately $27 million in aggregate gross proceeds to implement its BNB treasury strategy, managed through five-year agreements with Cypress LLC for Strategic Digital Assets Services and Cypress Management LLC as Strategic Advisor.
While pursuing its digital asset strategy, Applied DNA continues to commercialize nucleic acid production solutions through its LineaRx subsidiary. The company's LineaDNA™, LineaRNAP™, and LineaIVT™ platforms enable cell-free manufacturing of DNA and RNA for therapeutic and diagnostic applications, maintaining the company's technological foundation while expanding into digital assets.
This corporate transformation represents a notable example of traditional biotechnology companies diversifying into cryptocurrency and digital asset management. The move signals growing corporate interest in digital asset treasury strategies as companies seek alternative approaches to capital efficiency and shareholder value creation. Applied DNA's dual approach of maintaining operational technology expertise while implementing a digital asset strategy reflects the evolving landscape of corporate finance and investment strategies in the digital age.
The company's participation in B2i Digital's Featured Company program will include dedicated digital content, investor presentations, and regular updates designed to communicate Applied DNA's strategic transformation at scale. This comprehensive investor outreach through platforms such as Reddit and Threads aims to build awareness of the company's new strategic direction among both existing and potential investors.
